Sean K. Kelley - Concepedia

Author

Sean K. Kelley

Pennsylvania State University

Also Known As

S K Kelley, S KELLEY, S. K. Kelley, S. Kelley, S.J. Kelley, S.K. Kelley, Sean K Kelley, Sean K. Kelley, Sean Kelley

Publications

3.4K

Citations

H-Index

Concepts

All Affiliations

Pennsylvania State University Seagen (United States)Bechtel (United States)Tennessee Oncology Sarah Cannon

About

Sean K. Kelley is an author at Pennsylvania State University specializing in medicine, pharmacology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	736
2	Public Health	2	2	155
3	Health Sciences	1	1	34
4	Biochemistry	1	1	50
5	Cell Biology	1	1	28

Sean K. Kelley

Publications

Citations

H-Index

Page 1

	Year	Citations
Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer Roy S. Herbst, David H. Johnson, Eric D. Mininberg, Journal of Clinical Oncology	2005	535
Preclinical Studies to Predict the Disposition of Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Humans: Characterization of in Vivo Efficacy, Pharmacokinetics, and Safety Sean K. Kelley, Louise A. Harris, David Xie, Journal of Pharmacology and Experimental Therapeutics	2001	442
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma1 Michael D. Prados, Kathleen R. Lamborn, Susan M. Chang, Neuro-Oncology PathologyPharmacotherapyHigh-grade GliomasMetronomic ChemotherapyGlioma	2006	216
Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer J.F. Liu, Kathleen N. Moore, Michael J. Birrer, Annals of Oncology Pancreatic CancerMedicinePharmacologyPlatinum-resistant Ovarian CancerCancer Treatment	2016	132
Plasma Thyroid Hormone Kinetics Are Altered in Iron-Deficient Rats John L. Beard, D. Brigham, Sean K. Kelley, Journal of Nutrition Endocrine MechanismIodine Deficiency DisordersPhysiologyThyroid DiseaseThyroid Disorders	1998	105
Phase I Trial of Irinotecan, Infusional 5-Fluorouracil, and Leucovorin (FOLFIRI) with Erlotinib (OSI-774) Wells A. Messersmith, Daniel A. Laheru, Neil Senzer, Clinical Cancer Research	2004	83
TISSUE DISTRIBUTION, STABILITY, AND PHARMACOKINETICS OF APO2 LIGAND/TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND IN HUMAN COLON CARCINOMA COLO205 TUMOR-BEARING NUDE MICE Hong Xiang, Cindy Nguyen, Sean K. Kelley, Drug Metabolism and Disposition	2004	70
Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti‐CD40 antibody (SGN‐40) in rodents and non‐human primates Sean K. Kelley, Thomas Gelzleichter, Dong Xie, British Journal of Pharmacology Clinical ImmunologyVivo Pharmacokinetics PropertiesImmunologyImmune RegulationImmunodominance	2006	59
Preclinical pharmacokinetics, pharmacodynamics and activity of a humanized anti‐CD40 antibody (SGN‐40) in rodents and non‐human primates Sean K. Kelley, Thomas Gelzleichter, Dong Xie, British Journal of Pharmacology	2007	58
33 Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma Michael Prados, Susan M. Chang, Eric Burton, European Journal of Cancer Supplements Tumoral PathologyMedicineMetronomic TherapyMalignant GliomaPathology	2003	56

Page 1